PerspectiveCancer

Hidden Immunotherapy Targets Challenge Dogma

Science Translational Medicine  07 Sep 2011:
Vol. 3, Issue 99, pp. 99ps38
DOI: 10.1126/scitranslmed.3002821

You are currently viewing the abstract.

View Full Text

Log in


Abstract

In this issue of Science Translational Medicine, Guo et al. discuss the intriguing possibility that intracellular tumor antigen–specific monoclonal antibodies (mAbs) inhibit tumor growth and metastasis and prolong survival of tumor-bearing mice. Here, I discuss the implications of using intracellular targets in mAb-based immunotherapy as well as the possible underlying mechanisms of action.

Footnotes

  • Citation: S. Ferrone, Hidden Immunotherapy Targets Challenge Dogma. Sci. Transl. Med. 3, 99ps38 (2011).

View Full Text